 TORONTO--BUSINESS WIRE--FSD Pharma Inc. Nasdaq: HUGE CSE: HUGE FSD Pharma or the Company today announced the dosing of the first patient in its Phase 2a clinical trial of FSD201 ultramicronized palmitoylethanolamide, or ultramicronized PEA for the treatment of hospitalized patients with COVID-19. COVID-19 Trial Design The FSD201 COVID-19 Trial is a randomized, controlled, double-blind, multicenter study, conducted on 352 patients to assess the efficacy and safety of FSD201 dosed a 